Piromelatine
Phase 2Small molecule
Piromelatine is one of 89 small molecule programs targeting Cognition. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
191 competitors in Cognition
#DrugCompanyPhaseTrials
1Activella
Eli LillyPreclinical
Estrace
Novo NordiskPreclinical
Ozempic
Novo NordiskPreclinical
Galvus
NovartisPreclinical
Depo-Provera
PfizerPreclinical
Resotran
TakedaPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Marinol
Alnylam PharmaceuticalsPreclinical
Veramyst
GSKPreclinical
Florinef
Alnylam PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Piromelatine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNeurim Pharmaceuticals Ltd.